Stockscreener 앱 받기
3.82
1.04%
-0.02
Chimerix Inc 주식(CMRX)의 최신 뉴스
Assenagon Asset Management S.A. Has $2.85 Million Holdings in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Chimerix stock soars to 52-week high, hits $3.8 - MSN
Here’s Why Chimerix, Inc. (CMRX) Is Skyrocketing - MSN
Chimerix, Inc. (NASDAQ:CMRX) Sees Large Decline in Short Interest - MarketBeat
Why These 24 Stocks Are Skyrocketing - Insider Monkey
Chimerix to Speak Today at The White House Cancer Moonshot Forum - The Manila Times
Chimerix CSO to Present at Biden Cancer Moonshot Forum on Breakthrough Brain Cancer Treatment - StockTitan
Geode Capital Management LLC Trims Holdings in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Chimerix stock soars to 52-week high, hits $3.73 By Investing.com - Investing.com South Africa
Chimerix (NASDAQ:CMRX) Shares Pass Above 50-Day Moving AverageHere's What Happened - MarketBeat
Chimerix stock soars to 52-week high, hits $3.73 - Investing.com
Chimerix asks FDA to approve oral dordaviprone as glioma treatment - Myeloma Research News
H.C. Wainwright reiterates Buy rating on Chimerix stock amid NDA submission for ONC201 - Investing.com Canada
Buy rating reaffirmed on Chimerix stock with potential 3Q25 launch for ONC201 - Investing.com Australia
Buy rating reaffirmed on Chimerix stock with potential 3Q25 launch for ONC201 By Investing.com - Investing.com South Africa
Chimerix (NASDAQ:CMRX) Given Buy Rating at HC Wainwright - Defense World
Chimerix (NASDAQ: CMRX) Enters Amended Loan Agreement with Silicon Valley Bank - Defense World
Chimerix takes pivotal step for novel brain cancer drug - The Business Journals
A Glimpse Into The Expert Outlook On Chimerix Through 4 Analysts - Benzinga
Chimerix's (CMRX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Chimerix, Inc. Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma - Marketscreener.com
Chimerix (CMRX) Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma - StreetInsider.com
Chimerix Files FDA Application for Novel Brain Cancer Drug Dordaviprone, Secures $30M Launch Funding - StockTitan
Chimerix stock soars to 52-week high, hits $3.44 By Investing.com - Investing.com Nigeria
Chimerix stock soars to 52-week high, hits $3.44 - Investing.com India
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update - MarketBeat
Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Drop in Short Interest - MarketBeat
Biodefense Market CAGR of 7.3% Size, Growth Drivers and Forecast 2024-2031 | XOMA corporation, Altimmune Inc., - EIN News
Wedbush Weighs in on Chimerix’s Q4 Earnings (NASDAQ:CMRX) - Defense World
HC Wainwright Has Positive Outlook of Chimerix Q4 Earnings - Defense World
HC Wainwright Has Bullish Forecast for Chimerix Q4 Earnings - MarketBeat
Drugmaker seeks accelerated breakthrough for brain cancer treatment - The Business Journals
Wedbush Analysts Reduce Earnings Estimates for Chimerix - MarketBeat
Wedbush Brokers Lower Earnings Estimates for Chimerix - MarketBeat
3 Penny Stocks to Watch Now, 12/12/24 - TipRanks
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy (NASDAQ:CMRX) - Seeking Alpha
Chimerix (NASDAQ:CMRX) Earns Buy Rating from HC Wainwright - MarketBeat
Chimerix stock touches 52-week high at $2.20 amid market fluctuations - Investing.com Canada
Chimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer Dr - Asianet Newsable
Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Can - GuruFocus.com
3 Promising Penny Stocks With Market Caps Under $2B In US - Simply Wall St
S&P 500 Edges Lower; AutoZone Posts Downbeat EarningsAutoZone (NYSE:AZO), Chimerix (NASDAQ:CMRX) - Benzinga
Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer Therapy - Yahoo Finance
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings - Benzinga
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday? - AOL
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
0.96%
8.55%
자본화:
|
볼륨(24시간):